Interleukin 9 serum level and single nucleotide polymorphism in patients with asthma

Interleukin 9 serum level and single nucleotide polymorphism in patients with asthma

Authors

  • Seyed Alireza Mahdaviani 1- Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Mahsa Eskian 2- Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  • Mirhojjat Khorasanizadeh Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  • Bahram Bashardoost 1- Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Sabereh Tashayoie Nejad Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Hamid Reza Jamaati Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Arezou Rezaei Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  • Maryam Sadr Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  • Zahra Aryan Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  • Nima Rezaei a:1:{s:5:"en_US";s:4:"TUMS";}

Keywords:

ASTHMA, INTERLEUKIN-9, POLYMORPHISM

Abstract

Background:  Asthma is a chronic inflammatory disease of airways which accounts for a huge economic, morbidity and mortality burden. There are different cytokines that contribute to asthma pathophysiology. Learning about these cytokines leads to attaining novel anti-inflammatory treatments for asthma control.

Objectives: The objective of this study is to investigate the association between interleukin-9 serum level and gene polymorphism with asthma susceptibility.

Methods: This was a case-control study of 70 asthmatic patients and 77 healthy control adults aged 18-60. Asthma diagnosis and severity were based on physician diagnosis, pulmonary function test (PFT) and 2016 guild line of Global Initiative for Asthma (GINA). Interleukin 9(IL -9) serum level was measured using sandwich enzyme linked immunosorbent assay.  IL9 promoter single nucleotide polymorphism (SNP) (rs2069882) was also assessed using Real-Time PCR System.

Results: There was no significant association between IL-9 SNP polymorphism and asthma. IL-9 serum level was significantly associated with asthma susceptibility (p value= 0.016) and absolute eosinophil count (AEC) (P value=0.033) however its corelation with atopic asthma type, asthma sivierity and Immunoglubin E serum level were not statistically significant.

Conclusion: Although there was no association between IL-9 SNP and asthma, but IL-9 serum level was significantly correlated with asthma susceptibility and AEC.

References

Gauthier, M., A. Ray, and S.E. Wenzel, Evolving Concepts of Asthma. Am J Respir Crit Care Med, 2015. 192(6): p. 660-8.

Guidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute. National Asthma Education Program. Expert Panel Report. J Allergy Clin Immunol, 1991. 88(3 Pt 2): p. 425-534.

To, T., et al., Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health, 2012. 12: p. 204.

Prevention USCfDCa. National Surveillance of Asthma: United States, 2001–2010. Available from: http://www.cdc.gov/nchs/data/series/sr_03/sr03_035.pdf.

Wechsler, M.E., Getting control of uncontrolled asthma. Am J Med, 2014. 127(11): p. 1049-59.

Khorasanizadeh, M., et al., Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Ralpha, in Uncontrolled Eosinophilic Asthma. Int Rev Immunol, 2016. 35(4): p. 294-311.

Khorasanizadeh, M., et al., Mitogen-activated protein kinases as therapeutic targets for asthma. Pharmacol Ther, 2017.

Loftus, P.A. and S.K. Wise, Epidemiology and economic burden of asthma. Int Forum Allergy Rhinol, 2015. 5 Suppl 1: p. S7-10.

Hambly, N. and P. Nair, Monoclonal antibodies for the treatment of refractory asthma. Curr Opin Pulm Med, 2014. 20(1): p. 87-94.

Yssel, H. and H. Groux, Characterization of T cell subpopulations involved in the pathogenesis of asthma and allergic diseases. Int Arch Allergy Immunol, 2000. 121(1): p. 10-8.

Soussi-Gounni, A., M. Kontolemos, and Q. Hamid, Role of IL-9 in the pathophysiology of allergic diseases. J Allergy Clin Immunol, 2001. 107(4): p. 575-82.

Zhou, Y., M. McLane, and R.C. Levitt, Th2 cytokines and asthma. Interleukin-9 as a therapeutic target for asthma. Respir Res, 2001. 2(2): p. 80-4.

Xing, J., Y. Wu, and B. Ni, Th9: a new player in asthma pathogenesis? J Asthma, 2011. 48(2): p. 115-25.

Farahani, R., et al., Cytokines (interleukin-9, IL-17, IL-22, IL-25 and IL-33) and asthma. Adv Biomed Res, 2014. 3: p. 127.

Global Initiative for Asthma (GINA). 2012 revision. [April 13, 2017]]; Available from: www.ginasthma.com.

Miller, M.R., et al., Standardisation of spirometry. Eur Respir J, 2005. 26(2): p. 319-38.

Antunes, J., et al., Skin prick tests and allergy diagnosis. Allergol Immunopathol (Madr), 2009. 37(3): p. 155-64.

Waldman, I.D. and B.F. Robinson, Meta-analysis of sib pair linkage studies of asthma and the interleukin-9 gene (IL9). Genet Epidemiol, 2001. 21 Suppl 1: p. S109-14.

Wang, T.N., et al., The synergistic effects of the IL-9 gene and environmental exposures on asthmatic Taiwanese families as determined by the transmission/disequilibrium test. Int J Immunogenet, 2006. 33(2): p. 105-10.

Marsh, D.G., et al., Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations. Science, 1994. 264(5162): p. 1152-6.

Noguchi, E., et al., Evidence for linkage between asthma/atopy in childhood and chromosome 5q31-q33 in a Japanese population. Am J Respir Crit Care Med, 1997. 156(5): p. 1390-3.

Laitinen, T., et al., Genetic control of serum IgE levels and asthma: linkage and linkage disequilibrium studies in an isolated population. Hum Mol Genet, 1997. 6(12): p. 2069-76.

Hizawa, N., et al., Genetic influences of chromosomes 5q31-q33 and 11q13 on specific IgE responsiveness to common inhaled allergens among African American families. Collaborative Study on the Genetics of Asthma (CSGA). J Allergy Clin Immunol, 1998. 102(3): p. 449-53.

Louahed, J., et al., IL-9 induces expression of granzymes and high-affinity IgE receptor in murine T helper clones. J Immunol, 1995. 154(10): p. 5061-70.

Dugas, B., et al., Interleukin-9 potentiates the interleukin-4-induced immunoglobulin (IgG, IgM and IgE) production by normal human B lymphocytes. Eur J Immunol, 1993. 23(7): p. 1687-92.

Kearley, J., et al., IL-9 governs allergen-induced mast cell numbers in the lung and chronic remodeling of the airways. Am J Respir Crit Care Med, 2011. 183(7): p. 865-75.

Raeiszadeh Jahromi, S., et al., IL-10 and IL-17F Promoter Single Nucleotide Polymorphism and Asthma: A Case-Control Study in South India. Lung, 2015. 193(5): p. 739-47.

Desai, D. and C. Brightling, Cytokine and anti-cytokine therapy in asthma: ready for the clinic? Clin Exp Immunol, 2009. 158(1): p. 10-9.

Finiasz, M., et al., The role of cytokines in atopic asthma. Curr Med Chem, 2011. 18(10): p. 1476-87.

Desai, D. and C. Brightling, Cytokines and cytokine-specific therapy in asthma. Adv Clin Chem, 2012. 57: p. 57-97.

Downloads

Published

01-07-2021

Issue

Section

ORIGINAL ARTICLES

How to Cite

1.
Interleukin 9 serum level and single nucleotide polymorphism in patients with asthma. Acta Biomed [Internet]. 2021 Jul. 1 [cited 2024 Mar. 29];92(3):e2021206. Available from: https://mattioli1885journals.com/index.php/actabiomedica/article/view/10544